Therapeutic considerations for Mdm2: not just a one trick pony

Author： Lehman Jason A Eitel Jacob A Batuello Christopher N Mayo Lindsey D

ISSN： 1746-0441

Source： Expert Opinion on Drug Discovery, Vol.3, Iss.11, 2008-11, pp. : 1309-1321

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

MDM2 Splice Variants and Their Therapeutic Implications

Current Cancer Drug Targets, Vol. 5, Iss. 1, 2005-02 ,pp. : 21-26

Bentham Science Publishers

Access to resources Recommend Favorite

The MDM2 Inhibitor Nutlins as an Innovative Therapeutic Tool for the Treatment of Haematological Malignancies

Current Pharmaceutical Design, Vol. 14, Iss. 21, 2008-07 ,pp. : 2100-2110

Bentham Science Publishers

Access to resources Recommend Favorite

Editorial [Hot Topic: MDM2 as a Cancer Therapeutic Target (Guest Editor: Ruiwen Zhang)]

Current Cancer Drug Targets, Vol. 5, Iss. 1, 2005-02 ,pp. : 1-2

Bentham Science Publishers

Access to resources Recommend Favorite

MDM2 Non-Genotoxic Inhibitors as Innovative Therapeutic Approaches for the Treatment of Pediatric Malignancies

Current Medicinal Chemistry, Vol. 20, Iss. 17, 2013-06 ,pp. : 2226-2236

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting MDM2 and MDMX in Retinoblastoma

Current Cancer Drug Targets, Vol. 7, Iss. 7, 2007-11 ,pp. : 689-695

Bentham Science Publishers

Access to resources Recommend Favorite